News & Videos - AMRYT PHARMA ORD 6P

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Acromegaly patients were exposed to M ycapssa® during the g lobal Open - Label Extension ( OLE ) of the MPOWERED Phase 3 Trial for a maxim um of 3.5 years. - Patients switching from injectable Somatostatin Receptor Ligands (iSRLs) to M ycapssa® during the OLE...

Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6 , 2022 , Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“ Amryt ” or the “ Company ”) , a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases , today reminds shareholders of the key dates concerning the cancellation of the admission of its ordinary shares of nominal value £0.0 6 each (the “ Ordinary Shares ”)...

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa ® (oral octreotide) in Acromegaly P atients DUBLIN, Ireland, and Boston MA, January 4 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that The Lancet Diabetes & Endocrinology has published the full results of the global Phase 3 MPOWERED...

Total Voting Rights DUBLIN, Ireland, and Boston M A, January 4 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on December 31, 2021 the issued share capital of the Company comprised 319,814,747 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of...

Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on November 30, 2021 the issued share capital of the Company comprised 319,657,247 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting...

Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Ray Stafford 2 Reason for the notification a)...

Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now expected in January 2022 DUBLIN, Ireland, and Boston MA, November 23 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the US Food and Drug Administration (“FDA”) has extended the review...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A...

Amryt Reports Strong Q3 2021 Results 14.6% YoY revenue growth in Q3 to $56.5M 21.5% growth in metreleptin revenues YoY to $36.3M in Q3; 51.6% growth YoY excluding the impact of sporadic LATAM orders 7 th consecutive quarter of positive EBITDA generation excluding Chiasma transaction costs Cash of $123.2M at September 30, 2021 Reaffirming FY 2021 revenue guidance to $220M - $225M, representing 20-23% YoY growth Conference call and webcast today at 0830 EDT / 1230 GMT DUBLIN, Ireland, and Boston...

Total Voting Rights DUBLIN, Ireland, and Boston MA, November 1 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on October 31, 2021 the issued share capital of the Company comprised 317,999,117 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting...

A mryt to Report Q 3 202 1 Results and Host Conference Call & Webcast on November 3 DUBLIN, Ireland, and Boston MA, October 20 , 202 1 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases , today announces that its unaudited financial results for the third quarter 2021 will be released on Wednesday , November 3 , 2021 at 0700 E D T /1 1 00 GMT . Amryt will host a...

Amryt Announces New Patents for Oleogel-S10 and Mycapssa® DUBLIN, Ireland, and Boston MA, October 19 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its lead development candidate, Oleogel-S10, and its recently acquired and third commercial product, Mycapssa®. Oleogel-S10 The United States Patent and Trademark...

Total Voting Rights DUBLIN, Ireland, and Boston MA, Octo ber 1 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on September 30, 2021 the issued share capital of the Company comprised 316,904,642 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting...

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M Representing 20% - 23% YoY growth Virtual Capital Markets Event today at 1000-1200 EDT DUBLIN, Ireland, and Boston MA, September 13, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is today pleased to announce the raising of Amryt’s current full year 2021 revenue guidance. Given the recent...

Total Voting Rights DUBLIN, Ireland, and Boston MA, September 1 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on August 31, 2021 the issued share capital of the Company comprised 316,496,087 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting...

Amryt Issues Ordinary Shares and Total Voting Right s DUBLIN, Ireland, and Boston MA, August 19 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that as part of the acquisition of Chiasma, Inc. (“Chiasma”) by Amryt on August 5, 2021, (the “Transaction”) and further to the announcement on such date, Amryt will issue 7,015 additional new ordinary...

Director / PDMR Disclosure Options Granted to Non-Executive Directors DUBLIN, Ireland, and Boston MA, August 10, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on August 9, 2021, the following option awards over ordinary shares of £0.06 in the Company (“Shares”) were granted under the Amryt Pharma Plc Equity Incentive Plan to the following...

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT DUBLIN, Ireland, and Boston MA, August 9 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, will host a Virtual Capital Markets Event for Analysts and Investors on Monday, September 13, 2021, from 1000 – 1200 (EDT). Presentations will include an update on Amryt’s long-term strategy, the...

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance Acquisition of Chiasma completed Amryt now has three approved commercial products and a robust clinical pipeline 35.9% YoY revenue growth in Q2 to $62.8M 6 th consecutive quarter of positive EBITDA generation Cash increased to $142.9M at June 30 from $118.6M at March 31 Oleogel-S10 NDA accepted by the FDA, Priority Review granted; target PDUFA date set for November 30, 2021 Raising FY 2021 revenue guidance to $210M - $215M,...

Amryt Successfully Completes Acquisition of Chiasma, Inc. Appoints Raj Kannan and Dr. Roni Mamluk as Non-Executive Directors Issues Ordinary Shares and Total Voting Right s DUBLIN, Ireland, and Boston MA, August 5, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that it has completed its previously announced acquisition of Chiasma, Inc....